<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72030">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01699542</url>
  </required_header>
  <id_info>
    <org_study_id>CDM00049674</org_study_id>
    <nct_id>NCT01699542</nct_id>
  </id_info>
  <brief_title>WallFlex Esophageal Fully Covered (FC) Benign Anastomotic Stricture</brief_title>
  <official_title>A Multi-Center, Prospective, Randomized (RCT) Study Comparing WallFlexÂ® Esophageal Fully Covered (FC) Metal Stent to Bougie Dilation for the Treatment of Refractory Anastomotic Esophageal Strictures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <authority>Brazil: ANVISA Approval</authority>
    <authority>Netherlands: Dutch Health Care Inspectorate</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this of this study is to compare the safety and effectiveness of temporary
      indwell of the WallFlex Esophageal FC Metal Stent to Bougie Dilation for the treatment of
      refractory anastomotic esophageal strictures
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of procedures</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of dilation procedures for the management of dysphagia within 12 months following initial study treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical stent placement success defined as the ability to deploy the stent in satisfactory position across the stricture</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical stent removal success defined as the ability to remove the stent without complications.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's satisfaction with therapy</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's report of pain</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality Of Life (QOL): Improvement in EQ-5D-5L</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient diary to assess dysphagia scores</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Economic Endpoint</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Length of procedures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Economic Endpoint</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of outpatient procedures, office visits and ER</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Economic Endpoint</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number and length of hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Title:   Health Economic Endpoint</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of devices used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoint</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Occurrence and severity of adverse events related to the stent/bougie dilator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Endpoint</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to recurrence of dysphagia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Endpoint</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Incidence of stent migration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Endpoint</measure>
    <time_frame>12  months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of reinterventions within 12 months following the initial study treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Refractory Anastomotic Esophageal Strictures</condition>
  <arm_group>
    <arm_group_label>Metal Stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The WallFlex Biliary Fully Covered Esophageal Stent System is being evaluated for treatment of refractory anastomotic esophageal strictures.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bougie Dilation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Esophageal Bougie Dilator commercially available devices used per Investigator preference are being evaluated for treatment of refractory anastomotic esophageal strictures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>WallFlex Esophageal RX Fully Covered Stent</intervention_name>
    <description>Temporary placement of the WallFlex Esophageal RX Fully Covered Stent for treatment of refractory anastomotic esophageal strictures. The stent will be removed after 8 weeks (plus or minus 7 days) indwell</description>
    <arm_group_label>Metal Stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Esophageal Bougie Dilator Per Investigator preference</intervention_name>
    <description>Commercially available Esophageal Bougie Dilator Per Investigator preference</description>
    <arm_group_label>Bougie Dilation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Esophageal anastomotic stricture post esophagectomy (esophagogastric
        strictures).

          -  Esophagectomy performed at the same institution where patient enrollment and
             follow-up is planned.

          -  Two dilations to at least 16 mm in diameter since esophagectomy.

          -  1st dilation no more than 6 months post esophagectomy and 2nd dilation within 6
             months of 1st dilation to 16mm.

          -  Dysphagia score of 2 (ability to swallow semi-solid foods), 3 (ability to swallow
             liquids only) or 4 (unable to swallow liquids) at baseline.

          -  Unable to pass a standard endoscope (approx. 9.8 mm diameter).

          -  Age 18 years or older.

          -  Willing and able to comply with the study procedures and provide

        Exclusion Criteria:Stricture within 2 cm of the upper esophageal sphincter.

          -  Dysphagia related to motility disorder.

          -  Non-anastomotic esophageal strictures.

          -  Esophagocolonic strictures.

          -  Planned adjuvant radiation therapy post esophagectomy.

          -  Prior esophageal stent placements post esophagectomy.

          -  Active erosive esophagitis.

          -  Sensitivity to any components of the stent or delivery system.

          -  Concurrent medical condition that would affect the investigator's ability to evaluate
             the patient's condition or could compromise patient safety. Participation in a
             clinical trial evaluating an investigational device within 3 months prior to
             enrollment in this study.

          -  Stricture length &gt; 5 cm.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter D. Siersema, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pooja Goswamy</last_name>
    <phone>508-683-4335</phone>
    <email>pooja.goswamy@bsci.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea Burbage</last_name>
    <phone>508-683-4387</phone>
    <email>andrea.burbage@bsci.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto do Cancer do Estado de Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05612-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fauze Maluf, MD</last_name>
      <phone>551191919014</phone>
      <email>fauze.maluf@terra.com.br</email>
    </contact>
    <investigator>
      <last_name>Fauze Maluf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <state>CE</state>
        <zip>3015</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Bruno, MD</last_name>
      <phone>310107035946</phone>
    </contact>
    <investigator>
      <last_name>Marco Bruno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanin van Hooft, MD</last_name>
      <phone>31205667918</phone>
      <email>j.e.vanhooft@amc.uva.nl</email>
    </contact>
    <investigator>
      <last_name>Jeanin van Hooft, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter D. Siersema, MD</last_name>
      <phone>31887559338</phone>
      <email>p.d.siersema@umcutrecht.nl</email>
    </contact>
    <investigator>
      <last_name>Peter D. Siersema, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitets Sjukhuset</name>
      <address>
        <city>Stockholm</city>
        <zip>S-14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Urban Arnelo, MD</last_name>
      <phone>46858586937</phone>
      <email>urban.arnelo@ki.se</email>
    </contact>
    <investigator>
      <last_name>Urban Arnelo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Netherlands</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 4, 2014</lastchanged_date>
  <firstreceived_date>October 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Refractory Anastomotic esophageal strictures</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Esophageal Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
